Nexalin Technology (NXL) Leases (2022 - 2023)
Nexalin Technology's quarterly Leases came in at $496.0 in Q4 2023, down 91.96% year-on-year from $6171.0 in Q4 2022, and down 74.73% quarter-over-quarter from $1963.0 in Q3 2023.
Nexalin Technology has reported Leases for 2 years, with the latest figure at $496.0 in Q4 2023.
- For the quarter ending Q4 2023, Leases fell 91.96% year-over-year to $496.0; the trailing twelve-month figure through Dec 2023 stood at $496.0 (down 91.96% YoY), and the FY2023 full-year result was $496.0, down 91.96% from the prior year.
- Leases for Q4 2023 stood at $496.0, down from $1963.0 in the prior quarter.
- The five-year high for Leases was $7512.0 in Q3 2022, with the low at $496.0 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 547.00 Mn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 99.30 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 73.10 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 396.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 155.20 Mn |
| 10 | Nexalin Technology | 11.19 Mn | 8.48 Mn | 13,133.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 496.00 |
| Sep 30, 2023 | 1,963.00 |
| Jun 30, 2023 | 3,397.00 |
| Mar 31, 2023 | 4,800.00 |
| Dec 31, 2022 | 6,171.00 |
| Sep 30, 2022 | 7,512.00 |